加载中
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
前收盘价
US$2.78
+US$0.085 · +3.15%
盘前
US$2.78
US$0.00 · 0.00%
10月12日 6:01 ET
盘中时间采用ET。市场数据可能有所延迟。
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
日内区间
当前US$2.78
52周区间
当前US$2.78
盘中时间采用ET。市场数据可能有所延迟。
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
日内区间
当前US$2.78
52周区间
当前US$2.78
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 5274.4万 USD | 5339.9万 USD | 6549.4万 USD | 4763.8万 USD | 3835万 USD |
| 销货成本 | 2750.8万 USD | 2431.9万 USD | 2298.2万 USD | 1959.2万 USD | 1634.9万 USD |
| 毛利 | 2523.6万 USD | 2908万 USD | 4251.2万 USD | 2804.6万 USD | 2200.1万 USD |
| 研究与开发 | 1905.4万 USD | 1297万 USD | 1709.3万 USD | 2934.9万 USD | 2973.4万 USD |
| 销售、一般及管理费用 | 1168.2万 USD | 1219.3万 USD | 1495.9万 USD | 1171.1万 USD | 1272.9万 USD |
| 营业费用 | 3073.6万 USD | 2516.3万 USD | 3205.2万 USD | 4106万 USD | 4246.3万 USD |
| 利息收入 | 108.3万 USD | 129.9万 USD | 128.6万 USD | 114.6万 USD | 40.1万 USD |
| 利息支出 | 119.1万 USD | 106.2万 USD | 318万 USD | 252.9万 USD | 752.1万 USD |
| 折旧和摊销 | 146.5万 USD | 130.4万 USD | 119.1万 USD | 108.6万 USD | 111.8万 USD |
| 营业利润 | −550万 USD | 391.7万 USD | 1046万 USD | −1301.4万 USD | −2046.2万 USD |
| 净利润 | −660.4万 USD | 293.2万 USD | 831.2万 USD | −1492.7万 USD | −2758.2万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$6.00
上涨空间 115.83%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2019年12月20日 | 1:10 | — | — |
股票拆分 | 2007年1月3日 | 1:10 | — | — |
已生效 2019年12月20日
1:10
已生效 2007年1月3日
1:10
报告持有此股票敞口的交易所交易基金。
iShares Russell 2000 ETFIWM533.29万0.01%787.4亿 USD0.19%US$278.94+0.49%
Schwab International Small-Cap Equity ETFSCHC244.54万0.04%55.33亿 USD0.06%US$49.47+0.84%
iShares Russell 2000 Growth ETFIWO201.18万0.01%139.17亿 USD0.24%US$356.78+0.94%
State Street SPDR Portfolio Developed World ex-US ETFSPDW196.2万0.00%404.62亿 USD0.03%US$49.98+0.64%
Vanguard Russell 2000 ETFVTWO108.99万0.01%180亿 USD0.06%US$112.66+0.50%
iShares Micro-Cap ETFIWC68.47万0.05%13.17亿 USD0.60%US$183+0.11%
Dimensional - US Small Cap ETFDFAS67.84万0.00%338.69亿 USD0.31%US$78.35+0.32%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM27万0.23%1.17亿 USD0.73%US$15.9402+0.25%iShares Russell 2000 ETFIWMSchwab International Small-Cap Equity ETFSCHCiShares Russell 2000 Growth ETFIWOState Street SPDR Portfolio Developed World ex-US ETFSPDWVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCDimensional - US Small Cap ETFDFASEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
